In This Section

AACR-SITC Congressional Briefing

Progress in Immuno-oncology: Delivering Hope and Clinical Benefit to Cancer Patients

Date: July 19, 2017. Watch the briefing video.

One of the most promising areas of cancer research is the
field of immuno-oncology. Scientists are discovering new ways to arm a patient’s immune system so that it can attack cancer cells, and the result has been one of the most transformative approaches to cancer treatment that has ever entered the clinic. For many patients, cancer immunotherapies are already providing lifesaving results where other treatments had failed or were not viable. But realizing more breakthroughs in this area and broadening the scope of cancers that can be treated with immuno-oncology requires a
sustained, federal investment in cancer research through the National Institutes of Health and the National Cancer Institute.

The American Association for Cancer Research and the Society
for Immunotherapy of Cancer are pleased to host this briefing that will highlight some of the exciting innovations that are being delivered through immuno-oncology, illustrate the hope that these advances are bringing to cancer patients, and note the challenges that still need to be overcome so that even more cancer patients can benefit from these revolutionary treatments.

Confirmed Speakers:

  • Elizabeth M. Jaffee, MD, AACR president-elect 2017-2018; deputy director, The Sidney Kimmel
    Comprehensive Cancer Center at Johns Hopkins in Baltimore
  • Lisa H. Butterfield, PhD, president, SITC; professor of medicine, surgery and immunology; and director,
    UPCI Immunologic Monitoring and Cellular Products Laboratory, University of
  • Steven A. Rosenberg, MD, PhD, chief of surgery, National Cancer Institute, Bethesda, Maryland
  • Bernard A. Fox, PhD, past-president, SITC; chief, Laboratory of Molecular and Tumor Immunology,
    Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute,
    Providence Cancer Center
  • Daniel S. Chen, MD, PhD, vice president, global head of cancer immunotherapy development, Genentech
  • Stefanie Joho, colon cancer survivor and patient advocate